Non-valvular Atrial Fibrillation
Conditions
Interventions
Rivaroxavan will be orally administered at a dose of 15 mg once daily after evening meal. The administration will start one month before ablation and last until one month after that.
Warfarin will be
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who fulfill all of the following criteria 1. Be diagnosed non-valvular atrial fibrillation 2. Be scheduled for catheter ablation procedure for AF 3. Has a left atrial diameter <= 55 mm 4. Be aged from 20 to 80 years 5. Sign an informed consent document by himself/herself
Exclusion criteria
Exclusion criteria: Patients who fulfill at least one of the following criteria 1. Has a history of a prior stroke or TIA within 6 months before enrollment 2. Has a history of a major bleeding within 12 months before enrollment 3. Has had major surgery including CABG within 6 months before enrollment 4. Has a history of a MI within 2 months before catheter ablation procedure 5. Has a CrCl < 30 mL/min at screening 6. Has a diagnosis or clinical condition requiring use of dual anti-platelet therapy 7. Has contraindications of rivaroxaban or warfarin 8. Be a patient judged as "inappropriate" by an investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of asymptomatic cerebral infarction caused by catheter ablation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. the occurrence of post-procedural (30-40 days) major bleeding event 2. the occurrence of post-procedural (30-40 days) thromboembolic event | — |
Countries
Japan
Contacts
Public ContactSeiji Takatsuki
Keio University School of Medicine Department of Cardiology
Outcome results
None listed